Taiko Pharmaceutical Co (TSE:4574) Other Stockholders Equity: 円317 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
66 GF Score
Price 円278.00
GF Value 円339.43
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co Other Stockholders Equity?

Taiko Pharmaceutical Co TSE:4574 +1.83% 66 Other Stockholders Equity is 円317 Mil as of Dec. 2025. GuruFocus rates TSE:4574 with a GF Score™ of 66/100 and a GF Value™ of 円339.43 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Taiko Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was 円317 Mil.

Taiko Pharmaceutical Co's quarterly Other Stockholders Equity declined from Jun. 2025 (円391 Mil) to Sep. 2025 (円289 Mil) but then increased from Sep. 2025 (円289 Mil) to Dec. 2025 (円317 Mil).

Taiko Pharmaceutical Co's annual Other Stockholders Equity increased from Dec. 2023 (円454 Mil) to Dec. 2024 (円703 Mil) but then declined from Dec. 2024 (円703 Mil) to Dec. 2025 (円317 Mil).

Taiko Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Other Stockholders Equity Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 210.00 309.00 454.00 703.00 317.00

Taiko Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 426.00 391.00 289.00 317.00 324.00
TSE:4574
66GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiko Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円317 Mil mean?
Taiko Pharmaceutical Co (TSE:4574) has a Other Stockholders Equity of 円317 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Taiko Pharmaceutical Co and its competitors.
Is Taiko Pharmaceutical Co's Other Stockholders Equity too high?
Taiko Pharmaceutical Co's current Other Stockholders Equity is 円317 Mil. Overall, Taiko Pharmaceutical Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Other Stockholders Equity compare to ZTS and UTHR?
Taiko Pharmaceutical Co's Other Stockholders Equity of 円317 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Taiko Pharmaceutical Co and its competitors. Taiko Pharmaceutical Co's current Other Stockholders Equity is 円317 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Modestly Undervalued. The stock's GF Value™ is 円339.43, compared to a current price of 円278.00 — trading 18.1% below its estimated fair value. The current Other Stockholders Equity is 円317 Mil. Taiko Pharmaceutical Co's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Other Stockholders Equity is 円317 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円278.00 is trading 18.1% below its estimated GF Value™ of 円339.43. GuruFocus considers Taiko Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4574:

  • Other Stockholders Equity: 円317 Mil
  • GF Value™: 円339.43 vs. price of 円278.00 (18.1% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
66GF Score

Get the complete analysis for TSE:4574

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円278.00
Price
円339.43
GF Value